A recent report from the Business Monitor outlines India's strong commercial opportunities for pharmaceutical companies, but government issues are increasingly making the country less attractive on many subsectors of pharma, including the regulation of clinical trials.
The Business Monitor offers a risk/reward rating for countries, and India scored a 51.8 out of a possible 100, which is below the regional average for most indicators under industry and country risks. In addition, India ranked 10th behind New Zealand out of the 19 key markets in the Asia-Pacific.
The full release can be read here.
